Institution
University of Kansas
Education•Lawrence, Kansas, United States•
About: University of Kansas is a education organization based out in Lawrence, Kansas, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 38183 authors who have published 81381 publications receiving 2986312 citations. The organization is also known as: KU & Univ of Kansas.
Topics: Population, Poison control, Health care, Context (language use), Cancer
Papers published on a yearly basis
Papers
More filters
•
22 Jan 1991TL;DR: Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for oral, intranasal, or parenteral administration are disclosed in this paper.
Abstract: Sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water insoluble drugs for oral, intranasal, or parenteral administration are disclosed.
762 citations
••
TL;DR: In this article, a combination of graphical and statistical analyses were performed on a 12-month time-series of MODIS EVI and NDVI data from more than 2000 cropped field sites across the U.S. state of Kansas.
756 citations
••
Memorial Sloan Kettering Cancer Center1, Cornell University2, University of Michigan3, Institut Gustave Roussy4, University of Verona5, University of Kansas6, Baylor University Medical Center7, Mayo Clinic8, Memorial Hospital of South Bend9, Johns Hopkins University School of Medicine10, Seoul National University Hospital11, Fox Chase Cancer Center12, University of Chicago13, Katholieke Universiteit Leuven14, Incyte15, Hannover Medical School16
TL;DR: These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements.
Abstract: Summary Background Fibroblast growth factor receptor (FGFR) 2 gene alterations are involved in the pathogenesis of cholangiocarcinoma. Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3. This study evaluated the safety and antitumour activity of pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma with and without FGFR2 fusions or rearrangements. Methods In this multicentre, open-label, single-arm, multicohort, phase 2 study (FIGHT-202), patients aged 18 years or older with disease progression following at least one previous treatment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2 recruited from 146 academic or community-based sites in the USA, Europe, the Middle East, and Asia were assigned to one of three cohorts: patients with FGFR2 fusions or rearrangements, patients with other FGF/FGFR alterations, or patients with no FGF/FGFR alterations. All enrolled patients received a starting dose of 13·5 mg oral pemigatinib once daily (21-day cycle; 2 weeks on, 1 week off) until disease progression, unacceptable toxicity, withdrawal of consent, or physician decision. The primary endpoint was the proportion of patients who achieved an objective response among those with FGFR2 fusions or rearrangements, assessed centrally in all patients who received at least one dose of pemigatinib. This study is registered with ClinicalTrials.gov , NCT02924376 , and enrolment is completed. Findings Between Jan 17, 2017, and March 22, 2019, 146 patients were enrolled: 107 with FGFR2 fusions or rearrangements, 20 with other FGF/FGFR alterations, 18 with no FGF/FGFR alterations, and one with an undetermined FGF/FGFR alteration. The median follow-up was 17·8 months (IQR 11·6–21·3). 38 (35·5% [95% CI 26·5–45·4]) patients with FGFR2 fusions or rearrangements achieved an objective response (three complete responses and 35 partial responses). Overall, hyperphosphataemia was the most common all-grade adverse event irrespective of cause (88 [60%] of 146 patients). 93 (64%) patients had a grade 3 or worse adverse event (irrespective of cause); the most frequent were hypophosphataemia (18 [12%]), arthralgia (nine [6%]), stomatitis (eight [5%]), hyponatraemia (eight [5%]), abdominal pain (seven [5%]), and fatigue (seven [5%]). 65 (45%) patients had serious adverse events; the most frequent were abdominal pain (seven [5%]), pyrexia (seven [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]). Overall, 71 (49%) patients died during the study, most frequently because of disease progression (61 [42%]); no deaths were deemed to be treatment related. Interpretation These data support the therapeutic potential of pemigatinib in previously treated patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements. Funding Incyte Corporation.
756 citations
••
Karolinska University Hospital1, Karolinska Institutet2, Hospital of the University of Pennsylvania3, Great Ormond Street Hospital4, Brigham and Women's Hospital5, University of Kansas6, University of Alabama7, Mayo Clinic8, University of Pittsburgh9, Central Manchester University Hospitals NHS Foundation Trust10, University of Liverpool11, University of Debrecen12, University of Toronto13, University of Guadalajara14, University of Cambridge15, University of Tsukuba16, United States Department of Health and Human Services17, Tokyo Medical and Dental University18, Oregon State University19, Dalhousie University20, Peking University21, Duke University22, Oslo University Hospital23, New Generation University College24, Charles University in Prague25, National Institutes of Health26
TL;DR: New classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology and paediatric groups, and have been partially validated and generally perform better than existing criteria.
Abstract: Objective To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups. Methods Candidate variables were assembled from published criteria and expert opinion using consensus methodology. Data were collected from 47 rheumatology, dermatology, neurology and paediatric clinics worldwide. Several statistical methods were used to derive the classification criteria. Results Based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% adults; 18% children), new criteria were derived. Each item is assigned a weighted score. The total score corresponds to a probability of having IIM. Subclassification is performed using a classification tree. A probability cut-off of 55%, corresponding to a score of 5.5 (6.7 with muscle biopsy) ‘probable IIM’, had best sensitivity/specificity (87%/82% without biopsies, 93%/88% with biopsies) and is recommended as a minimum to classify a patient as having IIM. A probability of ≥90%, corresponding to a score of ≥7.5 (≥8.7 with muscle biopsy), corresponds to ‘definite IIM’. A probability of Conclusions The European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology and paediatric groups. They employ easily accessible and operationally defined elements, and have been partially validated. They allow classification of ‘definite’, ‘probable’ and ‘possible’ IIM, in addition to the major subgroups of IIM, including juvenile IIM. They generally perform better than existing criteria.
754 citations
••
United States Department of Energy1, J. Craig Venter Institute2, University of California, Berkeley3, Heidelberg University4, University of California, Irvine5, Technische Universität München6, National Institutes of Health7, Pomona College8, Salk Institute for Biological Studies9, University of Kiel10, National Institute of Genetics11, University of Vienna12, University of Kansas13, University of Innsbruck14, Dartmouth College15, North Carolina State University16, Ludwig Maximilian University of Munich17
TL;DR: Comparisons of the Hydra genome to the genomes of other animals shed light on the evolution of epithelia, contractile tissues, developmentally regulated transcription factors, the Spemann–Mangold organizer, pluripotency genes and the neuromuscular junction.
Abstract: The freshwater cnidarian Hydra was first described in 17021 and has been the object of study for 300 years. Experimental studies of Hydra between 1736 and 1744 culminated in the discovery of asexual reproduction of an animal by budding, the first description of regeneration in an animal, and successful transplantation of tissue between animals2. Today, Hydra is an important model for studies of axial patterning3, stem cell biology4 and regeneration5. Here we report the genome of Hydra magnipapillata and compare it to the genomes of the anthozoan Nematostella vectensis6 and other animals. The Hydra genome has been shaped by bursts of transposable element expansion, horizontal gene transfer, trans-splicing, and simplification of gene structure and gene content that parallel simplification of the Hydra life cycle. We also report the sequence of the genome of a novel bacterium stably associated with H. magnipapillata. Comparisons of the Hydra genome to the genomes of other animals shed light on the evolution of epithelia, contractile tissues, developmentally regulated transcription factors, the Spemann–Mangold organizer, pluripotency genes and the neuromuscular junction.
754 citations
Authors
Showing all 38401 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gordon H. Guyatt | 231 | 1620 | 228631 |
Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
Wei Li | 158 | 1855 | 124748 |
David Tilman | 158 | 340 | 149473 |
Tomas Hökfelt | 158 | 1033 | 95979 |
Pete Smith | 156 | 2464 | 138819 |
Daniel J. Rader | 155 | 1026 | 107408 |
Melody A. Swartz | 148 | 1304 | 103753 |
Kevin Murphy | 146 | 728 | 120475 |
Carlo Rovelli | 146 | 1502 | 103550 |
Stephen Sanders | 145 | 1385 | 105943 |
Marco Zanetti | 145 | 1439 | 104610 |
Andrei Gritsan | 143 | 1531 | 135398 |
Gunther Roland | 141 | 1471 | 100681 |
Joseph T. Hupp | 141 | 731 | 82647 |